Understanding how triple negative breast cancer adapts after chemotherapy
Metabolic adaptation in residual triple negative breast cancer following chemotherapy
This study is looking at how triple negative breast cancer cells adapt their energy use to survive after chemotherapy, and it aims to find new ways to target these changes to help improve treatment for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10988230 on NIH RePORTER |
What this research studies
This research investigates how triple negative breast cancer (TNBC) cells change their metabolism to survive after chemotherapy treatment. By examining tumor samples from patients before and after chemotherapy, the study aims to identify specific changes in mitochondrial function that contribute to treatment resistance. The researchers will use patient-derived models to explore these metabolic adaptations and test potential therapies that target these vulnerabilities. This approach could lead to new strategies for eliminating residual cancer cells and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have undergone neoadjuvant chemotherapy and have residual tumor cells.
Not a fit: Patients with non-triple negative breast cancer or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with residual triple negative breast cancer after chemotherapy.
How similar studies have performed: Previous research has shown that targeting metabolic pathways in cancer cells can be effective, suggesting that this approach may yield promising results.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Echeverria, Gloria Vittone — Baylor College of Medicine
- Study coordinator: Echeverria, Gloria Vittone
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.